Effects of growth hormone, prolactin and thyroxine on body wegith, somatomedin-like activity and in-vivo sulphation of cartilage in hypopituitary dwarf mice.
Hypopituitary dwarf mice were found to have reduced levels of serum somatomedin-like activity compared with normal mice of the Snell strain. Treatment with bovine growth hormone for 3 and 7 days resulted in growth without significantly increased levels of serum somatomedin-like activity, as detected by in-vitro uptake of 35SO4(2-) into normal rat cartilage; only after treatment for 14 days was somatomedin activity significantly raised. However, treatment for 2 days with bovine growth hormone, bovine prolactin or thyroxine resulted in a dose-dependent increase in in-vivo uptake of 35SO4(2-) into dwarf mouse costal cartilage; growth hormone and thyroxine did not act synergistically. Ten days of treatment with growth hormone promoted a dose-dependent increase in both growth (increased weight gain and tail length) and in-vivo of 35SO4(2-). Increase in tail length was correlated with uptake of 35S04(2-). Thus, in-vivo uptake of 35SO4(2-) into dwarf mouse costal cartilage provides a sensitive method for detecting a dose-related effect of growth hormone.
D000818:Animals; D001835:Body Weight / Q000187:drug effects*; D002356:Cartilage / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D004393:Dwarfism, Pituitary / Q000097:blood / Q000378:metabolism*; D005260:Female; D013006:Growth Hormone / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008817:Mice, Mutant Strains; D011388:Prolactin / Q000494:pharmacology*; D013002:Somatomedins / Q000097:blood*; D013431:Sulfates / Q000378:metabolism*; D013974:Thyroxine / Q000494:pharmacology*
D013002:Somatomedins; D013431:Sulfates; D011388:Prolactin; D013006:Growth Hormone; D013974:Thyroxine